Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03670355 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic and Safety Study of a 90 Day Intravaginal Ring Containing Tenofovir
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT03670355 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 49 participants.
The verdict
NCT03670355, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) and safety of a 90-day intravaginal ring (IVR) containing tenofovir (TFV).
Interventions
- DRUG Tenofovir (TFV) IVR
- DRUG Placebo IVR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2019-01-02 |
| Est. Completion | 2019-09-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03670355
The ClinicalTrials.gov registry entry for NCT03670355 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tenofovir (TFV) IVR is the first listed.
NCT03670355 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03670355 about?
NCT03670355 is a clinical study titled "Pharmacokinetic and Safety Study of a 90 Day Intravaginal Ring Containing Tenofovir". The purpose of this study is to evaluate the pharmacokinetics (PK) and safety of a 90-day intravaginal ring (IVR) containing tenofovir (TFV).
What is the current status of trial NCT03670355?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2019-01-02. Estimated completion is 2019-09-25.
What interventions are being tested in trial NCT03670355?
The interventions under investigation include: Tenofovir (TFV) IVR (DRUG), Placebo IVR (DRUG).
Who is sponsoring clinical trial NCT03670355?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.